A novel humanized anti-tumor necrosis factor-related apoptosis-inducing ligand-R2 monoclonal antibody induces apoptotic and autophagic cell death. 2017

Longfei Chen, and Yuhe Qiu, and Zhenliang Hao, and Jiong Cai, and Shuyong Zhang, and Yanxin Liu, and Dexian Zheng
Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

It is well known that the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/TNFSF10) is specifically expressed in various tumor cells, but less or no expression in most normal tissues and cells. While TRAIL engages with its native death receptors, TRAIL receptor 1 (TRAIL-R1) or 2 (TRAIL-R2), usually elicits the tumor cell death by apoptosis. In this study, we report that a novel humanized monoclonal antibody against TRAIL-R2 (named as zaptuzumab) well remain the biological activity of the parental mouse antibody AD5-10 inducing cell death in various cancer cells, but little effect on normal cells. Zaptuzumab also markedly inhibited the tumor growth in the mouse xenograft of NCI-H460 without toxicity to the liver and kidney, and the efficacy of tumor suppression was increased significantly while it combined with cis-dichlorodiamineplatinum. Especially, 131 I-labeled zaptuzumab injected into mouse tail vein specifically targeted to the xenograft of the lung cancer cells. Confocal analysis showed that zaptuzumab bound with TRAIL-R2 on cell surface could be quickly internalized and transferred into the lysosome. Furthermore, zaptuzumab possessed a high level of antibody-dependent cytotoxicity as well as complement-dependent cytotoxicity. Study on the mechanisms of cell death induced by zaptuzumab showed that it efficiently induced both caspase-dependent apoptosis and autophagic cell death. These data suggest that the humanized anti-TRAIL-R2 monoclonal antibody or the second generation of the antibody may have an important clinical usage for cancer immunotherapy. © 2017 IUBMB Life, 69(9):735-744, 2017.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000072283 A549 Cells An immortalized cell line derived from human ADENOCARCINOMA, ALVEOLAR basal epithelial cells isolated from the lungs of a male patient in 1972. The cell line is positive for KERATIN, can synthesize LECITHIN, and contains high levels of POLYUNSATURATED FATTY ACIDS in its PLASMA MEMBRANE. It is used as a model for PULMONARY ALVEOLI function and virus infections, as a TRANSFECTION host, and for PRECLINICAL DRUG EVALUATION. A549 Cell Line,A549 Cell,A549 Cell Lines,Cell Line, A549,Cell Lines, A549,Cell, A549,Cells, A549
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001343 Autophagy The segregation and degradation of various cytoplasmic constituents via engulfment by MULTIVESICULAR BODIES; VACUOLES; or AUTOPHAGOSOMES and their digestion by LYSOSOMES. It plays an important role in BIOLOGICAL METAMORPHOSIS and in the removal of bone by OSTEOCLASTS. Defective autophagy is associated with various diseases, including NEURODEGENERATIVE DISEASES and cancer. Autophagocytosis,ER-Phagy,Lipophagy,Nucleophagy,Reticulophagy,Ribophagy,Autophagy, Cellular,Cellular Autophagy,ER Phagy
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D053220 Receptors, TNF-Related Apoptosis-Inducing Ligand Tumor necrosis factor receptor family members that are widely expressed and play a role in regulation of peripheral immune responses and APOPTOSIS. The receptors are specific for TNF-RELATED APOPTOSIS-INDUCING LIGAND and signal via conserved DEATH DOMAINS that associate with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM. Decoy Receptor 2, Tumor Necrosis Factor,Receptors, TRAIL,Receptors, Tumor Necrosis Factor, Member 10,Receptors, Tumor Necrosis Factor, Member 10b,TNF-Related Apoptosis-Inducing Ligand Receptors,Tumor Necrosis Factor Receptor Superfamily, Member 10,APO2 Receptor,CD261 Antigen,CD262 Antigen,CD264 Antigen,DCR2 Receptor,DR4 Receptor,DR5 Receptor,Death Receptor-4,Death Receptor-5,Receptor, TRAIL-1,Receptor, TRAIL-2,Receptor, TRAIL-4,Receptors, Tumor Necrosis Factor, Member 10a,Receptors, Tumor Necrosis Factor, Member 10d,TNF-Related Apoptosis-Inducing Ligand Receptor 2,TRAIL Receptor 1,TRAIL Receptor 2,TRAIL Receptor 4,TRAIL Receptors,Tumor Necrosis Factor Receptor Superfamily, Member 10a,Tumor Necrosis Factor Receptor Superfamily, Member 10b,Antigen, CD261,Antigen, CD262,Antigen, CD264,Death Receptor 4,Death Receptor 5,Receptor 4, TRAIL,Receptor, APO2,Receptor, DCR2,Receptor, DR4,Receptor, DR5,Receptor, TRAIL 1,Receptor, TRAIL 2,Receptor, TRAIL 4,Receptor-4, Death,Receptors, TNF Related Apoptosis Inducing Ligand,TNF Related Apoptosis Inducing Ligand Receptor 2,TNF Related Apoptosis Inducing Ligand Receptors,TRAIL-1 Receptor,TRAIL-2 Receptor,TRAIL-4 Receptor
D053221 TNF-Related Apoptosis-Inducing Ligand A transmembrane-protein belonging to the TNF family of intercellular signaling proteins. It is a widely expressed ligand that activates APOPTOSIS by binding to TNF-RELATED APOPTOSIS-INDUCING LIGAND RECEPTORS. The membrane-bound form of the protein can be cleaved by specific CYSTEINE ENDOPEPTIDASES to form a soluble ligand form. Tumor Necrosis Factor Ligand Superfamily Member 10,Apo-2 Ligand,Apo-2L Protein,CD253 Antigen,TNF Superfamily, Member 10,TRAIL Protein,Antigen, CD253,Apo 2 Ligand,Apo 2L Protein,Apoptosis-Inducing Ligand, TNF-Related,TNF Related Apoptosis Inducing Ligand
D061067 Antibodies, Monoclonal, Humanized Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab. Antibodies, Humanized,Humanized Antibodies

Related Publications

Longfei Chen, and Yuhe Qiu, and Zhenliang Hao, and Jiong Cai, and Shuyong Zhang, and Yanxin Liu, and Dexian Zheng
May 2017, Oncology letters,
Longfei Chen, and Yuhe Qiu, and Zhenliang Hao, and Jiong Cai, and Shuyong Zhang, and Yanxin Liu, and Dexian Zheng
February 2006, International journal of oncology,
Longfei Chen, and Yuhe Qiu, and Zhenliang Hao, and Jiong Cai, and Shuyong Zhang, and Yanxin Liu, and Dexian Zheng
November 2003, Arthritis and rheumatism,
Longfei Chen, and Yuhe Qiu, and Zhenliang Hao, and Jiong Cai, and Shuyong Zhang, and Yanxin Liu, and Dexian Zheng
November 2009, Oncology reports,
Longfei Chen, and Yuhe Qiu, and Zhenliang Hao, and Jiong Cai, and Shuyong Zhang, and Yanxin Liu, and Dexian Zheng
November 2005, Endocrinology,
Longfei Chen, and Yuhe Qiu, and Zhenliang Hao, and Jiong Cai, and Shuyong Zhang, and Yanxin Liu, and Dexian Zheng
January 2014, Advances in experimental medicine and biology,
Longfei Chen, and Yuhe Qiu, and Zhenliang Hao, and Jiong Cai, and Shuyong Zhang, and Yanxin Liu, and Dexian Zheng
October 2005, Human pathology,
Longfei Chen, and Yuhe Qiu, and Zhenliang Hao, and Jiong Cai, and Shuyong Zhang, and Yanxin Liu, and Dexian Zheng
July 2005, Cancer letters,
Longfei Chen, and Yuhe Qiu, and Zhenliang Hao, and Jiong Cai, and Shuyong Zhang, and Yanxin Liu, and Dexian Zheng
December 2004, Journal of cellular physiology,
Longfei Chen, and Yuhe Qiu, and Zhenliang Hao, and Jiong Cai, and Shuyong Zhang, and Yanxin Liu, and Dexian Zheng
November 2011, Neuro-oncology,
Copied contents to your clipboard!